Appendix 3G
Notification of issue, conversion or payment up of equity & securities. Download...
Read More
Change in substantial holding
22 December 2020 Form 604 Corporations Act 2001 Section 671B Notice of...
Read More
CLINUVEL Newsletter VI
Dear shareholders, friends, CLINUVEL’S OUTLOOK The past weeks have seen a flurry...
Read More
SCIENTIFIC COMMUNIQUÉ VIII
DNA Repair Mechanisms December 2020 Introduction DNA is the repository of genetic...
Read More
SCENESSE® DNA REPAIR STUDY IN HEALTHY VOLUNTEERS APPROVED
Melbourne, Australia, 30 November 2020 CLINUVEL PHARMACEUTICALS LTD today announced that it...
Read More
SCIENTIFIC COMMUNIQUÉ VII
The Cerebral Vasculature System in Disease: Atherosclerosis Introduction The human brain is...
Read More
Jefferies Virtual London Healthcare Conference Presentation
20 November 2020 Download presentation & speaker’s notes
Read More
Chair's Letter To Shareholders
19 November 2020 Dear fellow shareholder, I look back at a year...
Read More
Results of Annual General Meeting
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...
Read More
MANAGING DIRECTOR’S PRESENTATION TO CLINUVEL ANNUAL GENERAL MEETING
The following is a transcript of the Managing Director’s presentation to the...
Read More
CHAIR’S ADDRESS TO CLINUVEL ANNUAL GENERAL MEETING
I am up for re-election today, thank you for those who supported...
Read More
CLINUVEL Strategic Update – Extended
CLINUVEL PHARMACEUTICALS LTD today released a strategic update on its business. An...
Read More
APPENDIX 4C AND ACTIVITY REPORT
KEY HIGHLIGHTS: SEPTEMBER QUARTER 2020 • Cash receipts of $12,015,000 • Operating...
Read More
CLINUVEL Strategic Update – Executive Summary
CLINUVEL PHARMACEUTICALS LTD today released a strategic update on its business. An...
Read More